Baseline demographics
| Characteristic . | Placebo . | Zosuquidar . | All patients . |
|---|---|---|---|
| No. of patients | 221 | 212 | 433 |
| Age, y | |||
| Median (IQR) | 69 (65-73) | 69 (65-73) | 69 (65-73) |
| < 70, no. (%) | 123 (55.7) | 113 (53.3) | 236 (54.5) |
| 70-79, no. (%) | 92 (41.6) | 96 (45.5) | 188 (43.4) |
| ≥ 80, no. (%) | 6 (2.7) | 3 (1.4) | 9 (2.1) |
| Female sex | 85 (38.5) | 103 (48.6) | 188 (43.4) |
| ECOG performance status | |||
| 0, no. (%) | 82 (37.1) | 48 (22.9) | 130 (30.2) |
| 1, no. (%) | 110 (49.8) | 103 (49.0) | 213 (49.4) |
| 2, no. (%) | 22 (10.0) | 45 (21.4) | 67 (15.5) |
| 3, no. (%) | 7 (3.2) | 14 (6.7) | 21 (4.9) |
| Not available | 0 | 2 | 2 |
| Median LVEF, % (IQR) | |||
| Pretreatment (no.) | 64 (60-68) | 63 (57-68) | 64 (58-68) |
| Characteristic . | Placebo . | Zosuquidar . | All patients . |
|---|---|---|---|
| No. of patients | 221 | 212 | 433 |
| Age, y | |||
| Median (IQR) | 69 (65-73) | 69 (65-73) | 69 (65-73) |
| < 70, no. (%) | 123 (55.7) | 113 (53.3) | 236 (54.5) |
| 70-79, no. (%) | 92 (41.6) | 96 (45.5) | 188 (43.4) |
| ≥ 80, no. (%) | 6 (2.7) | 3 (1.4) | 9 (2.1) |
| Female sex | 85 (38.5) | 103 (48.6) | 188 (43.4) |
| ECOG performance status | |||
| 0, no. (%) | 82 (37.1) | 48 (22.9) | 130 (30.2) |
| 1, no. (%) | 110 (49.8) | 103 (49.0) | 213 (49.4) |
| 2, no. (%) | 22 (10.0) | 45 (21.4) | 67 (15.5) |
| 3, no. (%) | 7 (3.2) | 14 (6.7) | 21 (4.9) |
| Not available | 0 | 2 | 2 |
| Median LVEF, % (IQR) | |||
| Pretreatment (no.) | 64 (60-68) | 63 (57-68) | 64 (58-68) |
The differences in sex and performance status between patients randomized to zosuquidar or placebo are statistically significant at P ≤ .042 and .0001, respectively.
LVEF indicates left ventricular ejection fraction.